1
|
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
|
N Engl J Med
|
1991
|
3.52
|
2
|
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
|
J Clin Oncol
|
2000
|
3.50
|
3
|
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
|
Clin Cancer Res
|
2000
|
2.86
|
4
|
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
|
Oncogene
|
2007
|
2.79
|
5
|
Flow cytometry in clinical cancer research.
|
Cancer Res
|
1983
|
2.72
|
6
|
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
|
Blood
|
2001
|
2.71
|
7
|
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
|
Leukemia
|
2002
|
2.68
|
8
|
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
|
Blood
|
2001
|
2.52
|
9
|
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells.
|
Gene Ther
|
2008
|
2.50
|
10
|
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens.
|
Am J Clin Pathol
|
1999
|
2.38
|
11
|
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.
|
J Exp Med
|
1984
|
2.26
|
12
|
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
|
J Clin Invest
|
2001
|
2.21
|
13
|
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
|
Blood
|
2000
|
2.11
|
14
|
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
|
N Engl J Med
|
1994
|
2.09
|
15
|
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
|
N Engl J Med
|
1993
|
2.09
|
16
|
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.
|
Blood
|
1992
|
2.07
|
17
|
Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.
|
Blood
|
1992
|
2.05
|
18
|
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
|
Science
|
1990
|
1.90
|
19
|
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
|
J Clin Oncol
|
1994
|
1.85
|
20
|
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
|
Leukemia
|
2008
|
1.84
|
21
|
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|
Cancer Res
|
1996
|
1.82
|
22
|
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
|
Blood
|
1999
|
1.76
|
23
|
Influenza among hospitalized adults with leukemia.
|
Clin Infect Dis
|
1997
|
1.68
|
24
|
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.
|
J Natl Cancer Inst
|
1997
|
1.63
|
25
|
The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles.
|
Handb Exp Pharmacol
|
2007
|
1.62
|
26
|
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
|
Leukemia
|
2002
|
1.62
|
27
|
Cytokine-regulated expression of survivin in myeloid leukemia.
|
Blood
|
2001
|
1.56
|
28
|
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
|
Blood
|
1991
|
1.56
|
29
|
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.
|
Leukemia
|
2008
|
1.53
|
30
|
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe.
|
Cytotherapy
|
2008
|
1.52
|
31
|
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
|
Blood
|
2000
|
1.52
|
32
|
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro.
|
Eur J Cancer
|
1992
|
1.51
|
33
|
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
|
Leukemia
|
2008
|
1.48
|
34
|
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
|
Leukemia
|
2005
|
1.44
|
35
|
The PML gene encodes a phosphoprotein associated with the nuclear matrix.
|
Blood
|
1995
|
1.44
|
36
|
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.
|
Leukemia
|
2003
|
1.39
|
37
|
Apoptosis. Molecules and mechanisms.
|
Adv Exp Med Biol
|
1999
|
1.30
|
38
|
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
|
Leukemia
|
2011
|
1.30
|
39
|
The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.
|
Leukemia
|
2005
|
1.30
|
40
|
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
|
Oncogene
|
1989
|
1.30
|
41
|
Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA.
|
Blood
|
1980
|
1.29
|
42
|
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
|
Blood
|
1991
|
1.27
|
43
|
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
|
Leukemia
|
2004
|
1.24
|
44
|
Apoptosis effector mechanisms: a requiem performed in different keys.
|
Apoptosis
|
2006
|
1.22
|
45
|
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
|
Clin Cancer Res
|
2000
|
1.22
|
46
|
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
|
Blood
|
1998
|
1.22
|
47
|
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
|
Blood
|
1995
|
1.18
|
48
|
Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia.
|
Clin Infect Dis
|
1995
|
1.17
|
49
|
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.
|
Clin Cancer Res
|
1996
|
1.17
|
50
|
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.
|
Leukemia
|
2003
|
1.16
|
51
|
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.
|
J Clin Oncol
|
1988
|
1.13
|
52
|
Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.
|
Gene Ther
|
1995
|
1.13
|
53
|
Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
|
Br J Haematol
|
1999
|
1.11
|
54
|
Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium.
|
Leuk Res
|
1981
|
1.11
|
55
|
Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes.
|
Blood
|
1996
|
1.11
|
56
|
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.
|
Oncogene
|
2011
|
1.11
|
57
|
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies.
|
Br J Haematol
|
1997
|
1.10
|
58
|
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Blood
|
1997
|
1.09
|
59
|
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
|
Leukemia
|
2009
|
1.09
|
60
|
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
|
Clin Cancer Res
|
1999
|
1.08
|
61
|
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
|
Cell Death Differ
|
2007
|
1.08
|
62
|
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.
|
Blood
|
1999
|
1.07
|
63
|
Characterization of hematologic malignancies by flow cytometry.
|
Blood Cells
|
1980
|
1.04
|
64
|
Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology.
|
Cytometry
|
1993
|
1.04
|
65
|
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
|
Leukemia
|
2011
|
1.03
|
66
|
hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
|
Gene Ther
|
2002
|
1.02
|
67
|
A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia.
|
Blood
|
1996
|
1.02
|
68
|
[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
|
Nuklearmedizin
|
2009
|
1.02
|
69
|
Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
|
Leukemia
|
2009
|
1.01
|
70
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
Leukemia
|
2011
|
1.01
|
71
|
Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
|
Cancer Res
|
1994
|
1.01
|
72
|
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
|
Blood
|
1995
|
1.00
|
73
|
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
|
J Clin Oncol
|
1995
|
1.00
|
74
|
Epidemiology of influenza A virus infection in patients with acute or chronic leukemia.
|
Support Care Cancer
|
1995
|
1.00
|
75
|
Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.
|
Int J Cancer
|
1998
|
0.99
|
76
|
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses.
|
Hum Gene Ther
|
2004
|
0.99
|
77
|
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
|
Clin Cancer Res
|
2000
|
0.98
|
78
|
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.
|
Cancer Gene Ther
|
2009
|
0.97
|
79
|
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
|
J Clin Oncol
|
1993
|
0.97
|
80
|
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes.
|
Blood
|
1998
|
0.97
|
81
|
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
|
Leukemia
|
2011
|
0.96
|
82
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
Blood
|
1999
|
0.96
|
83
|
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
|
Cell Death Differ
|
2007
|
0.95
|
84
|
Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.
|
Oncogene
|
2006
|
0.95
|
85
|
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
|
Am J Med
|
1998
|
0.95
|
86
|
Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells as revealed by flow cytometry.
|
J Histochem Cytochem
|
1979
|
0.94
|
87
|
PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation.
|
Leukemia
|
2004
|
0.94
|
88
|
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Blood
|
1996
|
0.93
|
89
|
Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.
|
Curr Pharm Des
|
2005
|
0.93
|
90
|
Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy.
|
Appl Radiat Isot
|
2000
|
0.92
|
91
|
Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment.
|
Cell Death Differ
|
1998
|
0.92
|
92
|
Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.
|
Leukemia
|
1998
|
0.92
|
93
|
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
|
Br J Haematol
|
1998
|
0.92
|
94
|
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
|
J Clin Oncol
|
1999
|
0.92
|
95
|
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
|
Ann Oncol
|
1999
|
0.92
|
96
|
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
|
Leukemia
|
2006
|
0.92
|
97
|
Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.
|
Leukemia
|
1990
|
0.92
|
98
|
Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
|
Cytometry
|
2000
|
0.91
|
99
|
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
|
Hum Gene Ther
|
2001
|
0.91
|
100
|
Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.
|
Leukemia
|
2006
|
0.91
|
101
|
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
|
Leukemia
|
2005
|
0.91
|
102
|
Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro.
|
Cancer Res
|
1990
|
0.91
|
103
|
Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
|
Bone Marrow Transplant
|
1996
|
0.90
|
104
|
Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells.
|
J Exp Med
|
1982
|
0.90
|
105
|
Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient.
|
Leukemia
|
2002
|
0.90
|
106
|
Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations.
|
Transplantation
|
1999
|
0.90
|
107
|
Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis.
|
Oncogene
|
1995
|
0.89
|
108
|
Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid.
|
Cancer Res
|
1993
|
0.89
|
109
|
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
J Clin Oncol
|
1999
|
0.89
|
110
|
Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells.
|
Br J Haematol
|
1998
|
0.89
|
111
|
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.
|
Leukemia
|
2011
|
0.89
|
112
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
Cancer
|
2001
|
0.89
|
113
|
A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas.
|
Cytometry
|
1994
|
0.89
|
114
|
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
|
Semin Oncol
|
1989
|
0.88
|
115
|
Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants.
|
Cancer Res
|
1990
|
0.87
|
116
|
CD30 ligand is expressed on resting normal and malignant human B lymphocytes.
|
Br J Haematol
|
1996
|
0.87
|
117
|
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
|
Am J Clin Pathol
|
1999
|
0.87
|
118
|
Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells.
|
Cell Growth Differ
|
1998
|
0.87
|
119
|
Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia.
|
Blood
|
1982
|
0.87
|
120
|
HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.
|
Leukemia
|
2012
|
0.87
|
121
|
Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen.
|
Blood
|
1997
|
0.87
|
122
|
Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
|
Oncogene
|
2006
|
0.87
|
123
|
CD30 ligand in lymphoma patients with CD30+ tumors.
|
J Clin Oncol
|
1997
|
0.87
|
124
|
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
|
Blood
|
1996
|
0.86
|
125
|
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
|
J Clin Oncol
|
1997
|
0.86
|
126
|
Acanthamoeba meningoencephalitis after bone marrow transplantation.
|
Bone Marrow Transplant
|
1994
|
0.86
|
127
|
Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
|
Cancer Res
|
1998
|
0.86
|
128
|
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
|
Leukemia
|
2009
|
0.86
|
129
|
Adenovirus as a gene therapy vector for hematopoietic cells.
|
Cancer Gene Ther
|
2000
|
0.86
|
130
|
Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.
|
Oncogene
|
1998
|
0.86
|
131
|
Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
|
Cytokines Mol Ther
|
1996
|
0.85
|
132
|
Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma.
|
Ann Intern Med
|
1983
|
0.85
|
133
|
Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma.
|
Cancer
|
1982
|
0.85
|
134
|
Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
|
Clin Cancer Res
|
1999
|
0.84
|
135
|
Cell kinetics in acute leukemia: a critical reevaluation based on new data.
|
Cancer
|
1982
|
0.84
|
136
|
Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia.
|
Blood
|
1993
|
0.84
|
137
|
Prognostic value of DNA/RNA flow cytometry of B-cell non-Hodgkin's lymphoma: development of laboratory model and correlation with four taxonomic systems.
|
Ann N Y Acad Sci
|
1986
|
0.84
|
138
|
Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.
|
Oncogene
|
2011
|
0.84
|
139
|
Discrimination of cycling and non-cycling lymphocytes by BUdR-suppressed acridine orange fluorescence in a flow cytometric system.
|
Exp Cell Res
|
1978
|
0.84
|
140
|
PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
|
Clin Cancer Res
|
1995
|
0.84
|
141
|
RNA content in human lymphocyte subpopulations.
|
Proc Natl Acad Sci U S A
|
1978
|
0.84
|
142
|
Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma.
|
Genes Chromosomes Cancer
|
1994
|
0.83
|
143
|
Allogeneic T cell activation triggering by MHC class I antigens.
|
J Immunol
|
1988
|
0.83
|
144
|
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor.
|
Blood
|
2001
|
0.83
|
145
|
Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
|
Apoptosis
|
2014
|
0.83
|
146
|
Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.
|
Leukemia
|
2010
|
0.83
|
147
|
Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
1999
|
0.83
|
148
|
All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway.
|
J Clin Invest
|
1998
|
0.83
|
149
|
Recognition of central nervous system leukemia by flow cytometry.
|
Cytometry
|
1984
|
0.82
|
150
|
Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.
|
Cancer Res
|
1992
|
0.82
|
151
|
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
|
Clin Cancer Res
|
1998
|
0.82
|
152
|
Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
|
Leukemia
|
1999
|
0.82
|
153
|
Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule.
|
Acta Haematol
|
1998
|
0.82
|
154
|
Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia.
|
Leuk Lymphoma
|
1995
|
0.81
|
155
|
Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.
|
Leuk Lymphoma
|
1995
|
0.81
|
156
|
Functional expression of TRAIL by lymphoid and myeloid tumour cells.
|
Br J Haematol
|
1999
|
0.81
|
157
|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
|
Am J Hematol
|
2001
|
0.81
|
158
|
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
|
Leukemia
|
1995
|
0.81
|
159
|
Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines.
|
Blood
|
1986
|
0.81
|
160
|
Acute lymphoblastic leukemia in adults.
|
Semin Oncol
|
1985
|
0.81
|
161
|
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
|
Leukemia
|
1989
|
0.81
|
162
|
Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60.
|
Exp Hematol
|
1981
|
0.81
|
163
|
Progression of nodular poorly differentiated lymphocytic lymphoma to Burkitt's-like lymphoma.
|
Blood
|
1984
|
0.81
|
164
|
Effect of very high-dose thymidine infusions on leukemia and lymphoma patients.
|
Cancer Res
|
1984
|
0.80
|
165
|
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
|
Proc Natl Acad Sci U S A
|
1995
|
0.80
|
166
|
S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy.
|
Cancer Epidemiol Biomarkers Prev
|
1997
|
0.80
|
167
|
Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing.
|
Hematol Cell Ther
|
1997
|
0.80
|
168
|
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
|
Blood
|
1998
|
0.80
|
169
|
Multiparameter flow cytometry. Part I: application in analysis of the cell cycle.
|
Clin Bull
|
1981
|
0.80
|
170
|
[Beta-radiation exposure at the finger tips during the radionuclide synovectomy].
|
Nuklearmedizin
|
2003
|
0.79
|
171
|
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
|
Cancer
|
1995
|
0.79
|
172
|
Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line.
|
Leuk Res
|
1998
|
0.79
|
173
|
Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes.
|
Blood
|
1997
|
0.79
|
174
|
[Oncogens and cancer. Review and a new method for measuring the gene expression in relation to the cell cycle].
|
Dtsch Med Wochenschr
|
1985
|
0.79
|
175
|
Retracted
Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression.
|
Blood
|
1991
|
0.79
|
176
|
CD38 in hematopoietic malignancies.
|
Chem Immunol
|
2000
|
0.79
|
177
|
DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation.
|
Br J Haematol
|
1985
|
0.79
|
178
|
Low incidence of MDR1 expression in acute promyelocytic leukaemia.
|
Br J Haematol
|
1995
|
0.79
|
179
|
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
|
Cytometry
|
1994
|
0.79
|
180
|
DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations.
|
Cancer
|
1991
|
0.78
|
181
|
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
|
Leukemia
|
1995
|
0.78
|
182
|
Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
|
Leukemia
|
1997
|
0.78
|
183
|
In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
|
Blood
|
1995
|
0.78
|
184
|
Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
|
Cancer Res
|
1984
|
0.78
|
185
|
Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation.
|
Int J Radiat Oncol Biol Phys
|
1983
|
0.78
|
186
|
Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.
|
Leukemia
|
2007
|
0.78
|
187
|
Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.
|
Mol Med
|
1998
|
0.78
|
188
|
Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material.
|
Leuk Res
|
1982
|
0.78
|
189
|
Cell kinetics of leukemia.
|
Semin Hematol
|
1986
|
0.78
|
190
|
[Ventilation-perfusion-lungscintigraphy using PET and 68Ga-labeled radiopharmaceuticals].
|
Nuklearmedizin
|
2010
|
0.78
|
191
|
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
|
Cytokines Mol Ther
|
1995
|
0.77
|
192
|
Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.
|
Blood
|
1996
|
0.77
|
193
|
Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence.
|
Gastroenterology
|
1996
|
0.77
|
194
|
Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells.
|
Cell Growth Differ
|
1996
|
0.77
|
195
|
Acute lymphoblastic leukemia following preleukemic syndromes in adults.
|
Leukemia
|
1996
|
0.77
|
196
|
Unbalanced expression of Fas and CD40 in mantle cell lymphoma.
|
Br J Haematol
|
1998
|
0.77
|
197
|
Biosynthesis of ferritin subunits from different cell lines of HL-60 human promyelocytic leukaemia cells and the release of acidic isoferritin-inhibitory activity against normal granulocyte-macrophage progenitor cells.
|
Br J Haematol
|
1983
|
0.77
|
198
|
Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting.
|
Leukemia
|
2001
|
0.77
|
199
|
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.
|
Leuk Lymphoma
|
1997
|
0.77
|
200
|
2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome.
|
Leukemia
|
1997
|
0.77
|
201
|
Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy.
|
Cancer Invest
|
1993
|
0.77
|
202
|
Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2.
|
Nat Immun
|
1998
|
0.77
|
203
|
Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission.
|
Br J Haematol
|
1997
|
0.76
|
204
|
Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
|
J Immunol
|
1998
|
0.76
|
205
|
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
|
Ann N Y Acad Sci
|
1986
|
0.76
|
206
|
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
|
Br J Cancer
|
2010
|
0.76
|
207
|
Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes.
|
Cancer Genet Cytogenet
|
1983
|
0.76
|
208
|
Sodium azide enhancement of interleukin-2 production.
|
Blood
|
1983
|
0.76
|
209
|
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
|
Br J Haematol
|
2001
|
0.76
|
210
|
Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation.
|
Clin Cancer Res
|
1999
|
0.76
|
211
|
Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
|
Clin Cancer Res
|
1998
|
0.76
|
212
|
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
|
Leuk Lymphoma
|
1993
|
0.76
|
213
|
Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides.
|
J Mol Med (Berl)
|
1996
|
0.76
|
214
|
Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection.
|
Br J Haematol
|
1995
|
0.76
|
215
|
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
|
Int J Cancer
|
1997
|
0.76
|
216
|
Surface immunoglobulin light chain expression in pre-B cell leukemias.
|
Ann N Y Acad Sci
|
1986
|
0.76
|
217
|
Heterogeneity of cell lineages in L3 leukemias.
|
Blood
|
1980
|
0.75
|
218
|
Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70.
|
Biochem Biophys Res Commun
|
1992
|
0.75
|
219
|
Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization.
|
Br J Haematol
|
1997
|
0.75
|
220
|
Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation.
|
Bone Marrow Transplant
|
1994
|
0.75
|
221
|
Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
1994
|
0.75
|
222
|
Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
|
Exp Hematol
|
1986
|
0.75
|
223
|
Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia.
|
Leukemia
|
1995
|
0.75
|
224
|
Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis.
|
Ann N Y Acad Sci
|
1986
|
0.75
|
225
|
Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts.
|
Med Pediatr Oncol Suppl
|
1992
|
0.75
|
226
|
High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement.
|
Cancer Genet Cytogenet
|
1994
|
0.75
|
227
|
Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol.
|
Cancer Invest
|
1985
|
0.75
|
228
|
T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
|
Transplant Proc
|
1992
|
0.75
|
229
|
DNA and RNA analysis by flow cytometry of the leukemia in AKR mice.
|
Leuk Res
|
1985
|
0.75
|
230
|
A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results.
|
Blood
|
1996
|
0.75
|
231
|
Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow.
|
Cytometry
|
1997
|
0.75
|
232
|
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia.
|
J Clin Oncol
|
1986
|
0.75
|
233
|
[Summary: Therapy of chronic myelogenous leukemia--prognosis].
|
Internist (Berl)
|
1980
|
0.75
|
234
|
CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease.
|
Ann Oncol
|
1997
|
0.75
|
235
|
Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline.
|
Oncol Rep
|
2011
|
0.75
|
236
|
Surface marker analysis and flow cytometric studies of acute nonlymphocytic leukemias in children and young adults.
|
Clin Immunol Immunopathol
|
1979
|
0.75
|
237
|
Multiparameter flow cytometry. Part II. application in hematology.
|
Clin Bull
|
1981
|
0.75
|
238
|
Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy.
|
Leuk Res
|
1986
|
0.75
|
239
|
Clonal stability and heterogeneity of hybridomas: analysis by multiparameter flow cytometry.
|
Hybridoma
|
1985
|
0.75
|
240
|
[Determination of radioactivity by smartphones].
|
Nuklearmedizin
|
2013
|
0.75
|
241
|
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
|
Exp Hematol
|
1992
|
0.75
|
242
|
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
|
Leukemia
|
1994
|
0.75
|
243
|
A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications.
|
Appl Radiat Isot
|
2008
|
0.75
|
244
|
Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC).
|
Bone Marrow Transplant
|
1989
|
0.75
|
245
|
Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization.
|
Cancer Genet Cytogenet
|
1995
|
0.75
|
246
|
Semi-automated PCR method for quantitating MDR1 expression.
|
Biotechniques
|
1996
|
0.75
|
247
|
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
|
Leuk Lymphoma
|
1998
|
0.75
|
248
|
Characterization of cultured human tumor cell lines by flow cytometry DNA stemline.
|
Anal Quant Cytol
|
1981
|
0.75
|
249
|
Acute non-lymphoblastic leukemia after treatment of nodular lymphoma with human leukocyte interferon.
|
Ann Intern Med
|
1983
|
0.75
|
250
|
[Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity].
|
Onkologie
|
1983
|
0.75
|
251
|
Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study.
|
Leukemia
|
1995
|
0.75
|
252
|
Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature.
|
Med Pediatr Oncol
|
1981
|
0.75
|
253
|
Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance.
|
Leukemia
|
1995
|
0.75
|
254
|
Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature.
|
Crit Rev Oncol Hematol
|
1986
|
0.75
|
255
|
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
|
Clin Cancer Res
|
1998
|
0.75
|
256
|
Quantitation of chemotherapy-induced cytoreduction in acute leukemia.
|
Haematol Blood Transfus
|
1981
|
0.75
|
257
|
Childhood CML in blastic stage: an analysis of cell markers and cell kinetics.
|
Am J Hematol
|
1980
|
0.75
|
258
|
The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis.
|
Blood
|
1979
|
0.75
|
259
|
[Autoregulatory growth inhibition in experimental tumors].
|
Verh Dtsch Ges Inn Med
|
1975
|
0.75
|
260
|
[Interpretation of differencies in the DNA-values of exfoliated cells in gynecologic smears (author's transl)].
|
Verh Dtsch Ges Pathol
|
1973
|
0.75
|
261
|
Idarubicin in acute leukemia: results of US trials.
|
Bone Marrow Transplant
|
1989
|
0.75
|
262
|
Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased?
|
Acta Haematol
|
1989
|
0.75
|
263
|
Cytokine expression of T cells in chronic myeloid leukemia.
|
Chin Med J (Engl)
|
2000
|
0.75
|
264
|
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
|
J Clin Apher
|
2001
|
0.75
|
265
|
[The value of impulse cytophotometry in the examination of ascitic fluid, contents of cysts and secretions from the cul-de-sac].
|
Geburtshilfe Frauenheilkd
|
1973
|
0.75
|
266
|
Molecular analysis of an AIDS-associated Burkitt's lymphoma: near-identity with endemic cases.
|
Curr Top Microbiol Immunol
|
1988
|
0.75
|
267
|
[3D segmenting method for volume quantification of ECT (emission-computed tomography) data].
|
Biomed Tech (Berl)
|
1998
|
0.75
|
268
|
GM-CSF in combination with cytotoxic chemotherapy in AML patients.
|
Bone Marrow Transplant
|
1990
|
0.75
|
269
|
Genetic therapy of human neoplastic disease.
|
J Hematother
|
1993
|
0.75
|
270
|
The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle.
|
Biochem Biophys Res Commun
|
1992
|
0.75
|
271
|
[Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment].
|
Internist (Berl)
|
1980
|
0.75
|
272
|
Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia.
|
Leukemia
|
1989
|
0.75
|
273
|
Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma.
|
Med Pediatr Oncol
|
1984
|
0.75
|
274
|
Retinoids and cancer therapy.
|
J Natl Cancer Inst
|
1992
|
0.75
|
275
|
[Effect of various new cytostatic agents on DNA reduplication and proliferation kinetics in the Ehrlich-Lettre ascites tumor model].
|
Verh Dtsch Ges Inn Med
|
1974
|
0.75
|
276
|
Minimal residual disease in hematologic malignancies.
|
Rev Invest Clin
|
1994
|
0.75
|
277
|
Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells.
|
Leuk Lymphoma
|
1995
|
0.75
|
278
|
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia.
|
Leukemia
|
1995
|
0.75
|
279
|
Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells.
|
Leuk Res
|
1987
|
0.75
|
280
|
Inhibition of telomerase activity correlates with a decrease in the RNA component of telomerase during differentiation.
|
Int J Oncol
|
1997
|
0.75
|
281
|
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
|
Blood
|
1991
|
0.75
|
282
|
Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations.
|
Leuk Lymphoma
|
1997
|
0.75
|
283
|
Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia.
|
Haematol Blood Transfus
|
1990
|
0.75
|
284
|
Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.
|
Leuk Lymphoma
|
1996
|
0.75
|
285
|
[Diastolic murmur caused by a phaeochromocytoma (author's transl)].
|
Dtsch Med Wochenschr
|
1975
|
0.75
|
286
|
[Effect of corrective procedures on volume quantification of SPECT data].
|
Biomed Tech (Berl)
|
1998
|
0.75
|
287
|
[Heart involvement in hemochromatosis].
|
Verh Dtsch Ges Inn Med
|
1971
|
0.75
|
288
|
Proliferation of human hematopoietic progenitors in long-term bone marrow cultures in gas-permeable plastic bags is enhanced by colony-stimulating factors.
|
Exp Hematol
|
1992
|
0.75
|
289
|
A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases.
|
Medinfo
|
1995
|
0.75
|
290
|
Flow cytometry. Clinical and research applications in hematologic malignancies.
|
Hematol Oncol Clin North Am
|
1994
|
0.75
|
291
|
Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.
|
Blood
|
1995
|
0.75
|
292
|
Flow cytometric analysis of cytokinetics of L3-acute lymphoblastic leukemia/lymphoma.
|
Leuk Res
|
1992
|
0.75
|
293
|
A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia.
|
Leuk Res
|
1990
|
0.75
|
294
|
Prognostic factors in acute lymphoblastic leukemia in adults: the Memorial Hospital experience.
|
Haematol Blood Transfus
|
1987
|
0.75
|